Evidence map›Paper›PMID 33641869›Full record

ReviewHematology/oncology clinics of North America2021

Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology.

Daniel Royston, Adam J Mead, Bethan Psaila

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematology/oncology clinics of North America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daniel RoystonNuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine and NIHR Biomedical Research Centre, University of Oxford, Headley Way, Oxford OX39DS, UK.
Adam J MeadMedical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR Biomedical Research Centre, University of Oxford, Headley Way, Oxford OX3 9DS, UK. Electronic address: adam.mead@imm.ox.ac.uk.
Bethan PsailaMedical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR Biomedical Research Centre, University of Oxford, Headley Way, Oxford OX3 9DS, UK.

Funding

Cancer Research UK 26988Cancer Research UK 27125Cancer Research UK 27723Cancer Research UK 28051Cancer Research UK 29034Cancer Research UK 30721Department of HealthMedical Research Council G84/6443Medical Research Council MR/L006340/1
6 · The paper itself

Abstract

Philadelphia-negative myeloproliferative neoplasms (MPNs) are an excellent tractable disease model of a number of aspects of human cancer biology, including genetic evolution, tissue-associated fibrosis, and cancer stem cells. In this review, we discuss recent insights into MPN biology gained from the application of a number of new single-cell technologies to study human disease, with a specific focus on single-cell genomics, single-cell transcriptomics, and digital pathology.

Indexed as

Myeloproliferative DisordersNeoplasmsSingle-Cell AnalysisFibrosisGene Expression ProfilingGenomicsHumansNeoplastic Stem CellsDigital pathologyMyeloproliferative neoplasmSingle-cell genomics

Identifiers

PMID33641869
PMCPMC7935666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.